BRAF Biomarkers
News and reporting on BRAF biomarkers.
FDA Approves Pfizer's Braftovi With Eli Lilly's Erbitux, Chemo in Colorectal Cancer
The agency granted accelerated approval to the regimen as a frontline option for advanced, BRAF V600E-mtuated tumors based on the BREAKWATER trial.
Boundless Bio Ends Trial of BBI-825 in Patients With Certain Cancer Resistance Mutations
Due to unfavorable pharmacokinetics and the development costs of BRAF V600E and KRAS G12C mutated cancers, the firm will not advance the STARMAP trial.
Tizona Therapeutics Expands Phase Ib Trial to Include Biomarker-Selected Colorectal Cancer Cohorts
In the new arms, patients with certain biomarker-defined tumors will receive either an HLA-G targeted antibody, chemo, and Erbitux, or just chemo and Erbitux.
Braftovi, Mektovi Approved in Europe for BRAF V600E-Mutant NSCLC
A Phase II trial of the combo demonstrated response rates of 75 percent and 46 percent in treatment-naïve and previously treated NSCLC patients, respectively.
Lung Cancer Groups Seek Public Comment on Updated Biomarker Testing Guidelines
Updated guidelines recommend certain biomarker tests for early- and late-stage lung cancer at the time of diagnosis.
May 16, 2024
Nov 29, 2023
Oct 12, 2023
Aug 23, 2023